{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:30:08Z","timestamp":1769315408951,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pigment Cell Melanoma Res"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study evaluated patterns of response as discerned by comprehensive metastasis\u2010specific analysis in metastatic melanoma patients receiving anti\u2010PD\u20101 antibodies. Bi\u2010dimensional measurements of every metastasis in patients enrolled in the KEYNOTE\u2010001 trial at a single institution were obtained at baseline and throughout treatment. Twenty\u2010seven evaluable patients had 399 baseline metastases measurable on CT imaging. Complete response (CR) which occurred in 52.6% of metastases was smaller (mean 223\u00a0mm<jats:sup>2<\/jats:sup> versus 760\u00a0mm<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.01) and occurred more frequently in the lungs (65% versus 39.4%, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.01). Response was heterogenous (new\/progressing metastases alongside CR metastases) at first assessment in 4\/14 patients with objective response (OR) as opposed to 7\/13 patients with non\u2010OR. CR of individual metastases is common and influenced by site and size. Most patients with OR demonstrate homogenous regression in all metastases at the first assessment. In contrast, patients with early heterogeneity had a poor outcome.<\/jats:p>","DOI":"10.1111\/pcmr.12675","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T07:02:43Z","timestamp":1511506963000},"page":"404-410","source":"Crossref","is-referenced-by-count":42,"title":["Metastasis\u2010specific patterns of response and progression with anti\u2010<scp>PD<\/scp>\u20101 treatment in metastatic melanoma"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-3444","authenticated-orcid":false,"given":"Jenny H. J.","family":"Lee","sequence":"first","affiliation":[{"name":"Departments of Biomedical Sciences and Clinical Medicine Macquarie University  Sydney NSW Australia"},{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"Crown Princess Mary Cancer Centre Westmead Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Lyle","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"},{"name":"Liz Plummer Cancer Care Centre Cairns Hospital  Cairns QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"},{"name":"Royal North Shore Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M. K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Gosford Hospital  Gosford NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne","family":"Lo","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Clements","sequence":"additional","affiliation":[{"name":"Norwest hospital  Sydney NSW Australia"},{"name":"Sydney Adventist Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"Crown Princess Mary Cancer Centre Westmead Hospital  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Kefford","sequence":"additional","affiliation":[{"name":"Departments of Biomedical Sciences and Clinical Medicine Macquarie University  Sydney NSW Australia"},{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"Crown Princess Mary Cancer Centre Westmead Hospital  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia  Sydney NSW Australia"},{"name":"University of Sydney  Sydney NSW Australia"},{"name":"Royal North Shore Hospital  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2212010280"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.04.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.308"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"abstr e20005","DOI":"10.1200\/jco.2015.33.15_suppl.e20005","article-title":"Patterns of acquired resistance to anti\u2010PD\u20101 antibodies in patients with metastatic melanoma (MM)","volume":"33","author":"Lee J. H. J.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"abstr 9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (met): The Anti\u2010PD1 Brain Collaboration","volume":"35","author":"Long G. V.","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12340"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"abstr 3012","DOI":"10.1200\/jco.2015.33.15_suppl.3012","article-title":"Efficacy based on tumor PD\u2010L1 expression in KEYNOTE\u2010002, a randomized comparison of pembrolizumab (pembro; MK\u20103475) versus chemotherapy in patients (pts) with ipilimumab\u2010refractory (IPI\u2010R) advanced melanoma (MEL)","volume":"33","author":"Puzanov I.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"abstr 9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204","volume":"35","author":"Tawbi H.","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2479"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"}],"container-title":["Pigment Cell &amp; Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcmr.12675","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcmr.12675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:39:38Z","timestamp":1695566378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcmr.12675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/pcmr.12675"],"URL":"https:\/\/doi.org\/10.1111\/pcmr.12675","archive":["Portico"],"relation":{},"ISSN":["1755-1471","1755-148X"],"issn-type":[{"value":"1755-1471","type":"print"},{"value":"1755-148X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}